Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Holaday

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
NIDA Research Monograph|January 1, 1986
In vivo interactions among opiate receptor agonists and antagonistsJ W Holaday, F C Tortella, R Maneckjee, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1993
The kappa opioid agonist U-50,488H antagonizes respiratory effects of mu opioid receptor agonists in conscious ratsK Dosaka-Akita, F C Tortella, J W Holaday, et al.
Proceedings of the Western Pharmacology Society|January 1, 1984
Dynorphin: cardiovascular consequences of opioid receptor interactions in normal and endotoxemic ratsJ W Holaday, J R Kenner, C E Glatt, et al.
Advances in Biochemical Psychopharmacology|January 1, 1982
Action of naloxone and TRH on the autonomic regulation of circulationJ W Holaday, R J D'Amato, B A Ruvio, et al.
Life Sciences|July 10, 1978
Failure vasopressin and oxytocin to antagonize acute morphine antinociception or facilitate narcotic tolerance developmentW K Schmidt, J W Holaday, H H Loh, et al.
Journal of the National Cancer Institute|October 8, 1999
Antiangiogenic activity of prostate-specific antigenA H Fortier, B J Nelson, D K Grella, et al.
Journal of Andrology|September 1, 1984
The role of endogenous opioid peptides in the control of androgen levels in the male nonhuman primateP M Gilbeau, R G Almirez, J W Holaday, et al.
Neuropeptides|December 1, 1984
ICI 174864, a putative delta opioid antagonist, reverses endotoxemic hypotension: pretreatment with dynorphin 1-13, A kappa agonist, blocks this actionJ B Long, B A Ruvio, C E Glatt, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1988
Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic functionJ B Long, J M Petras, W C Mobley, et al.
Central Nervous System Trauma : Journal of the American Paralysis Association|January 1, 1986
Endogenous opioids in spinal cord injury: a critical evaluationJ B Long, A Martinez-Arizala, J M Petras, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
NIDA Research Monograph|January 1, 1986
In vivo interactions among opiate receptor agonists and antagonistsJ W Holaday, F C Tortella, R Maneckjee, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1993
The kappa opioid agonist U-50,488H antagonizes respiratory effects of mu opioid receptor agonists in conscious ratsK Dosaka-Akita, F C Tortella, J W Holaday, et al.
Proceedings of the Western Pharmacology Society|January 1, 1984
Dynorphin: cardiovascular consequences of opioid receptor interactions in normal and endotoxemic ratsJ W Holaday, J R Kenner, C E Glatt, et al.
Advances in Biochemical Psychopharmacology|January 1, 1982
Action of naloxone and TRH on the autonomic regulation of circulationJ W Holaday, R J D'Amato, B A Ruvio, et al.
Life Sciences|July 10, 1978
Failure vasopressin and oxytocin to antagonize acute morphine antinociception or facilitate narcotic tolerance developmentW K Schmidt, J W Holaday, H H Loh, et al.
Journal of the National Cancer Institute|October 8, 1999
Antiangiogenic activity of prostate-specific antigenA H Fortier, B J Nelson, D K Grella, et al.
Journal of Andrology|September 1, 1984
The role of endogenous opioid peptides in the control of androgen levels in the male nonhuman primateP M Gilbeau, R G Almirez, J W Holaday, et al.
Neuropeptides|December 1, 1984
ICI 174864, a putative delta opioid antagonist, reverses endotoxemic hypotension: pretreatment with dynorphin 1-13, A kappa agonist, blocks this actionJ B Long, B A Ruvio, C E Glatt, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1988
Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic functionJ B Long, J M Petras, W C Mobley, et al.
Central Nervous System Trauma : Journal of the American Paralysis Association|January 1, 1986
Endogenous opioids in spinal cord injury: a critical evaluationJ B Long, A Martinez-Arizala, J M Petras, et al.
Pageof 15